The incidence, risk factors, and outcomes of acute graft-vs-host disease in pediatric T-cell-replete haploidentical hematopoietic stem cell transplantation.
Fei-Fei TangYi-Fei ChengLan-Ping XuXiao-Hui ZhangChen-Hua YanWei HanYu-Hong ChenXiao-Jun HuangYu WangPublished in: Pediatric transplantation (2020)
The specific description, risk factors, and outcomes of aGVHD in pediatric haplo-HSCT using TCR protocols without PT-Cy have not been well described previously. We evaluated the incidence, risk factors, and outcomes of aGVHD in 350 consecutive pediatric patients receiving TCR haplo-HSCT without PT-Cy according to the Glucksberg and NIH aGVHD classifications between January 2015 and December 2017 at Peking University Institute of Hematology. The cumulative incidences of grade I, II, III, and IV aGVHD were 28%, 29.7%, 8.3%, and 5.1%, respectively. The type of aGVHD onset was classic in 243 patients (97.2%), and persistent/recurrent/late-onset aGVHD was in seven patients (2.8%). None of the considered variables significantly influenced the incidence of grade III-IV aGVHD. The 3-year OS, DFS, cumulative incidence of NRM, and relapse in malignant disease between severe aGVHD (III-IV) group and grade 0-II aGVHD group were 61.5% vs 77.2% (P = .027), 58.6% vs 75.1% (P = .014), 19.8% vs 5.3% (P = .002), and 21.6% vs 19.6% (P = .59), respectively; in non-malignant diseases, the 3-year OS, DFS, and NRM were 81.8% vs 97.4% (P = .05), 81.8% vs 97.4% (P = .05), and 18.2% vs 2.6% (P = .05), respectively. Under the protocol of pediatric TCR haplo-HSCT without PT-Cy, the persistent/recurrent/late-onset aGVHD was rare, and the incidence of severe aGVHD was acceptable and significantly contributed to NRM and lower survival in both malignant disease and non-malignant diseases.
Keyphrases
- risk factors
- late onset
- early onset
- end stage renal disease
- newly diagnosed
- chronic kidney disease
- ejection fraction
- peritoneal dialysis
- regulatory t cells
- bone marrow
- prognostic factors
- type diabetes
- acute myeloid leukemia
- immune response
- low dose
- liver failure
- dendritic cells
- intensive care unit
- young adults
- metabolic syndrome
- free survival
- adipose tissue
- acute respiratory distress syndrome
- insulin resistance
- mechanical ventilation
- respiratory failure